European Journal of Cancer Q1 Unclaimed

Elsevier Ltd. United Kingdom
Unfortunately this journal has not been claimed yet. For this reason, some information may be unavailable.

European Journal of Cancer is a journal indexed in SJR in Oncology and Cancer Research with an H index of 214. Journal with a Single blind Peer Review review system, and It has a price of 2655 €. The scope of the journal is focused on Cancer, Oncology, Clinical Oncology, Medicine. It has an SJR impact factor of 3,354 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 3,354.

European Journal of Cancer focuses its scope in these topics and keywords: cancer, patients, cell, tumour, advanced, carcinoma, lung, colorectal, phase, factor, ...

Type: Journal

Type of Copyright:

Languages: English

Open Access Policy: Open Choice

Type of publications:

Publication frecuency: -

Price

2655 €

Inmediate OA

NPD

Embargoed OA

- €

Non OA

Metrics

European Journal of Cancer

3,354

SJR Impact factor

214

H Index

935

Total Docs (Last Year)

1157

Total Docs (3 years)

12549

Total Refs

7985

Total Cites (3 years)

961

Citable Docs (3 years)

6,51

Cites/Doc (2 years)

13,42

Ref/Doc

Aims and Scope


cancer, patients, cell, tumour, advanced, carcinoma, lung, colorectal, phase, factor, therapy, expression, inhibitor, receptor, chemotherapy, cd, rare, human, breast, survival, study, pembrolizumab, nonsmall, malignant, growth, Cancer, Oncology, Clinical Oncology, Medicine



Best articles by citations

I.4 Effects of anti-oestrogens on insulin-like growth factor (IGF-I) physiology systemically and in the uterus

View more

Maintaining abstinence from cigarette smoking: effectiveness of group counselling and factors predicting outcome

View more

74 O - Selective anti-leukemic potential of HLA-incompatible bone marrow transplants

View more

Surveillance for stage I testicular germ cell tumours

View more

Chromophilic renal cell carcinoma: Characterization of four permanent cell lines

View more

Is there a standard adjuvant treatment for rectal cancer?

View more

Metallothionein and Fas (CD95) are expressed in squamous cell carcinoma of the tongue

View more

Is the time interval between diagnosis and radiation treatment an important factor in brain metastases?

View more

The use of national registers of radiation exposure in occupational radiation risk assessment

View more

Apoptosis of Ovarian carcinoma cells (N1) by TNF and it's possible targets

View more

Time trends in ovarian cancer mortality in Europe (1955-1993)

View more

Bile duct stents: Is there an increased rate of complications in patients receiving chemotherapy?

View more
SHOW MORE ARTICLES

All-trans retinoic acid enhances gap junctional intercellular communication among renal epithelial cells in vitro treated with renal carcinogens

View more

Docetaxel in combination with 5-fluorouracil in patients with metastatic breast cancer previously treated with anthracycline-based chemotherapy

View more

163 O - Aortic infuslon (ADM, MMC, CDDP) and stop-flow (MMC, ADM) for systemically pretreated and progresslve FLGO III c and IV ovarian cancer-45 patients

View more

Combined intensive chemoradiotherapy for organ preservation in patients with resectable and non-resectable oesophageal cancer

View more

A novel herpes vector for the high efficiency transduction of primary hematopoietic cells

View more

nm23 Protein expression in larynx cancer and the relationship with metastasis

View more

Cancer information: a cost-effective intervention

View more

A high pretreatment serum level of VEGF is associated with poor outcome in small cell lung cancer

View more

26 P - Monitoring of neurotoxicity of taxanes

View more

A Glimpse of the Future. New Directions in the Treatment of Colorectal Cancer

View more

13-Cis-retinoic acid and alphainterferon in advanced squamous cell cancer of the oesophagus

View more

The role of desmosomal glycoproteins in the adhesion & invasion of human breast cancer cells

View more

Comments

No comments ... Be the first to comment!

FAQS